US IPO Pipeline SEC S-1 Filings — November 03, 2026

IPO Pipeline

By Gunpowder Editorial ·

1 high priority 1 total filings analysed

Executive Summary

The IPO Pipeline stream for 2026-11-03 contains a single filing: ADC Therapeutics SA's Form S-4 proposing redomiciliation from Switzerland to Delaware with continued NYSE listing under the ticker ADCT. The filing is a corporate-structure event rather than a new IPO or follow-on offering, so it sits at the edge of the stream's focus on registration activity.

Management's stated rationale centers on reduced duplicative regulatory costs, alignment with a predominantly U.S. operating base and investor base, Delaware corporate law flexibility, removal of Swiss limits on share issuance and preemptive rights, and elimination of PFIC exposure for U.S. holders. Because the enriched period-over-period, insider, capital allocation, and financial ratio fields are not populated for this filing, no cross-company trend or outlier analysis is possible. The transaction carries execution risk tied to shareholder approval, Swiss creditor, tax and Lex Koller rulings, and subsidiary restructuring, with a June 30, 2027 outside date. Sentiment is neutral and materiality is moderate at 6/10.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from November 02, 2026.

Investment Signals (2)

  • Redomiciliation to Delaware cites elimination of PFIC risk for U.S. holders and removal of Swiss share-issuance and preemptive-rights limits, a structural positive for capital-raising flexibility

  • Filing is neutral on sentiment with no enriched period comparisons, insider activity, or capital allocation data disclosed, so no quantitative directional signal can be extracted

Risk Flags (3)

  • Transaction is contingent on shareholder approval, Swiss creditor, tax and Lex Koller rulings, and subsidiary restructuring; failure to satisfy conditions by the June 30, 2027 outside date terminates the deal

  • Intercompany sale of certain IP to ADC Therapeutics America, Inc. and transfer of employees and agreements to a new Swiss subsidiary create tax, transfer-pricing and operational complexity during the transition

  • Multiple foreign regulatory and tax rulings (Swiss creditor, tax, and Lex Koller) are required, introducing timing uncertainty that may extend beyond expectations

Opportunities (2)

Sector Themes (1)

  • Cross-Border Redomiciliation to U.S.
    ◆

    ADC Therapeutics' move from Switzerland to Delaware reflects a broader pattern of non-U.S. issuers with predominantly U.S. operations consolidating under Delaware law to reduce dual-jurisdiction costs and PFIC exposure for U.S. holders; a single filing limits aggregate measurement

Watch List (3)

Filing Analyses (1)
ADC Therapeutics SA S-4 neutral materiality 6/10

03-11-2026

ADC Therapeutics SA filed a Form S-4 registration statement on November 3, 2026 for a proposed redomiciliation from Switzerland to Delaware, under which the company would become ADC Therapeutics, Inc. and continue trading on the NYSE as ADCT. Management cites reduced duplicative regulatory costs, closer alignment with its predominantly U.S. operations and investor base, Delaware corporate law flexibility, and removal of Swiss limits on share issuance and preemptive rights, as well as elimination of PFIC risk for U.S. holders. The transaction remains subject to shareholder approval, Swiss creditor, tax and Lex Koller rulings, subsidiary restructuring, and an outside date of June 30, 2027.

  • · Shareholders will vote on the Redomiciliation Proposal, Constitutive Documents Proposal and Discharge Proposal at a shareholder meeting
  • · Conditions include intercompany sale of certain IP from ADC Therapeutics SA to ADC Therapeutics America, Inc. and transfer of employees and agreements to a new Swiss subsidiary
  • · Transaction will not be consummated if conditions are not satisfied by June 30, 2027
  • · No changes expected to the board of directors or executive officers
  • · Principal executive offices will move to 430 Mountain Avenue, New Providence, New Jersey; registered agent is The Corporation Trust Company
  • · No material accounting effect or change in carrying amount of consolidated assets and liabilities; no pro forma financial statements included

Get daily alerts with 2 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 1 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US IPO Pipeline SEC S-1 Filings

🇺🇸 More from United States

View all →